HCK

Tyrosine-protein kinase HCK

97,674 patent compounds predicted against HCK, 76,675 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL130637	0.81	18/20
SCHEMBL130466	0.76	18/20
SCHEMBL130418	0.73	17/20
SCHEMBL130620	0.67	17/20
SCHEMBL130500	0.76	16/20
SCHEMBL12162	0.74	16/20
SCHEMBL129883	0.74	16/20
SCHEMBL130481	0.71	16/20
SCHEMBL129599	0.59	16/20
SCHEMBL10811	0.57	16/20
SCHEMBL130595	0.73	15/20
SCHEMBL129501	0.65	15/20
SCHEMBL129811	0.63	15/20
SCHEMBL129822	0.63	15/20
SCHEMBL129595	0.62	15/20
SCHEMBL129826	0.60	15/20
SCHEMBL129581	0.59	15/20
SCHEMBL130636	0.58	15/20
SCHEMBL149180	0.55	15/20
SCHEMBL130423	1.00	14/20

Germline variants in HCK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full HCK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to HCK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II Dasatinib Study in Advanced Breast Cancer	PHASE2	COMPLETED
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma	PHASE2	COMPLETED
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.	PHASE1/PHASE2	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy	PHASE2	COMPLETED
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	PHASE2	COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients	PHASE2	COMPLETED
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer	PHASE1/PHASE2	RECRUITING
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	PHASE1/PHASE2	RECRUITING
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma	PHASE2	UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
CD45BE-HSPC + CART-45 Cells	PHASE1	RECRUITING
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	ACTIVE_NOT_RECRUITING
Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers	PHASE1	COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL	PHASE1	WITHDRAWN
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy	PHASE1	COMPLETED
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL	PHASE1	COMPLETED
The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells	PHASE1	UNKNOWN
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)	nan	WITHDRAWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Ibrutinib Adapted to Response in Patients With CLL	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HCK binder may also engage these)

Protein	Name	Similarity
P50545	—	1.000	P50545 →
LYN	Tyrosine-protein kinase Lyn	1.000	landscape →
Q95M30	—	1.000	Q95M30 →
P25911	—	1.000	P25911 →
P08103	—	1.000	P08103 →
P06240	—	1.000	P06240 →
Q5PXS1	—	1.000	Q5PXS1 →
FYN	Tyrosine-protein kinase Fyn	1.000	landscape →
Q6EWH2	—	1.000	Q6EWH2 →
Q62844	—	1.000	Q62844 →
P10936	—	1.000	P10936 →
Q01621	—	1.000	Q01621 →
FGR	Tyrosine-protein kinase Fgr	0.999	landscape →
Q6P6U0	—	0.999	Q6P6U0 →
P42683	—	0.998	P42683 →
A1Y2K1	—	0.998	A1Y2K1 →
A1A5H8	—	0.997	A1A5H8 →
P00527	—	0.997	P00527 →
Q02977	—	0.997	Q02977 →
Q07014	—	0.997	Q07014 →
Q9V9J3	—	0.997	Q9V9J3 →
P27447	—	0.997	P27447 →
LCK	Tyrosine-protein kinase Lck	0.996	landscape →
P63185	—	0.996	P63185 →
P14234	—	0.996	P14234 →
F1LM93	—	0.996	F1LM93 →
P39688	—	0.996	P39688 →
YES1	Tyrosine-protein kinase Yes	0.996	landscape →
P09324	—	0.996	P09324 →
P13116	—	0.995	P13116 →